In December, it completed a merger with Aclara Biosciences, which is lookingat differences between normal and cancer cells to determine which signaling pathways a cancer cell is exploiting for replication.
Instead scientists and doctors are looking deeper at what is going wrong inside cancerous cells - a tumour can have 100, 000 genetic mutations and these alter over time.